União Europeia - português - EMA (European Medicines Agency)

virbac s.a. - tulatromicina - antibacterianos para uso sistêmico - cattle; pigs; sheep - cattle: treatment and metaphylaxis of bovine respiratory disease (brd) associated with mannheimia haemolytica, pasteurella multocida, histophilus somni and mycoplasma bovis susceptible to tulathromycin. a presença da doença no rebanho deve ser estabelecida antes do tratamento metafatológico. treatment of infectious bovine keratoconjunctivitis (ibk) associated with moraxella bovis susceptible to tulathromycin. pigs: treatment and metaphylaxis of swine respiratory disease (srd) associated with actinobacillus pleuropneumoniae, pasteurella multocida, mycoplasma hyopneumoniae, haemophilus parasuis and bordetella bronchiseptica susceptible to tulathromycin. a presença da doença no rebanho deve ser estabelecida antes do tratamento metafatológico. the product should only be used if pigs are expected to develop the disease within 2–3 days. ovinos: tratamento dos estágios iniciais da pododermatite infecciosa (podridão do pé) associada a dichelobacter nodosus virulento que requer tratamento sistêmico.

União Europeia - português - EMA (European Medicines Agency)

ceva santé animale - tulatromicina - antibacterianos para uso sistêmico - cattle; pigs; sheep - cattle: treatment and metaphylaxis of bovine respiratory disease (brd) associated with mannheimia haemolytica, pasteurella multocida, histophilus somni and mycoplasma bovis susceptible to tulathromycin. a presença da doença no rebanho deve ser estabelecida antes do tratamento metafatológico. treatment of infectious bovine keratoconjunctivitis (ibk) associated with moraxella bovis susceptible to tulathromycin. pigs: treatment and metaphylaxis of swine respiratory disease (srd) associated with actinobacillus pleuropneumoniae, pasteurella multocida, mycoplasma hyopneumoniae, haemophilus parasuis and bordetella bronchiseptica susceptible to tulathromycin. a presença da doença no rebanho deve ser estabelecida antes do tratamento metafatológico. the product should only be used if pigs are expected to develop the disease within 2–3 days. ovinos: tratamento dos estágios iniciais da pododermatite infecciosa (podridão do pé) associada a dichelobacter nodosus virulento que requer tratamento sistêmico.

União Europeia - português - EMA (European Medicines Agency)

vetoquinol - tulatromicina - antibacterianos para uso sistêmico - cattle; pigs; sheep - cattle: treatment and metaphylaxis of bovine respiratory disease (brd) associated with mannheimia haemolytica, pasteurella multocida, histophilus somni and mycoplasma bovis susceptible to tulathromycin. a presença da doença no rebanho deve ser estabelecida antes do tratamento metafatológico. treatment of infectious bovine keratoconjunctivitis (ibk) associated with moraxella bovis susceptible to tulathromycin. pigs: treatment and metaphylaxis of swine respiratory disease (srd) associated with actinobacillus pleuropneumoniae, pasteurella multocida, mycoplasma hyopneumoniae, haemophilus parasuis and bordetella bronchiseptica susceptible to tulathromycin. a presença da doença no rebanho deve ser estabelecida antes do tratamento metafatológico. the product should only be used if pigs are expected to develop the disease within 2–3 days. ovinos: tratamento dos estágios iniciais da pododermatite infecciosa (podridão do pé) associada a dichelobacter nodosus virulento que requer tratamento sistêmico.

União Europeia - português - EMA (European Medicines Agency)

elanco gmbh - tulatromicina - antibacterianos para uso sistêmico - cattle; pigs; sheep - cattle: treatment and metaphylaxis of bovine respiratory disease (brd) associated with mannheimia haemolytica, pasteurella multocida, histophilus somni and mycoplasma bovis susceptible to tulathromycin. a presença da doença no rebanho deve ser estabelecida antes do tratamento metafatológico. treatment of infectious bovine keratoconjunctivitis (ibk) associated with moraxella bovis susceptible to tulathromycin. pigs: treatment and metaphylaxis of swine respiratory disease (srd) associated with actinobacillus pleuropneumoniae, pasteurella multocida, mycoplasma hyopneumoniae, haemophilus parasuis and bordetella bronchiseptica susceptible to tulathromycin. a presença da doença no rebanho deve ser estabelecida antes do tratamento metafatológico. the product should only be used if pigs are expected to develop the disease within 2–3 days. ovinos: tratamento dos estágios iniciais da pododermatite infecciosa (podridão do pé) associada a dichelobacter nodosus virulento que requer tratamento sistêmico.

União Europeia - português - EMA (European Medicines Agency)

vmd n.v. - tulatromicina - antibacterials for systemic use, macrolides - cattle; pigs; sheep - cattle: treatment and metaphylaxis of bovine respiratory disease (brd) associated with mannheimia haemolytica, pasteurella multocida, histophilus somni and mycoplasma bovis susceptible to tulathromycin. a presença da doença no rebanho deve ser estabelecida antes do tratamento metafatológico. treatment of infectious bovine keratoconjunctivitis (ibk) associated with moraxella bovis susceptible to tulathromycin. pigs: treatment and metaphylaxis of swine respiratory disease (srd) associated with actinobacillus pleuropneumoniae, pasteurella multocida, mycoplasma hyopneumoniae, haemophilus parasuis and bordetella bronchiseptica susceptible to tulathromycin. a presença da doença no rebanho deve ser estabelecida antes do tratamento metafatológico. the product should only be used if pigs are expected to develop the disease within 2–3 days. ovinos: tratamento dos estágios iniciais da pododermatite infecciosa (podridão do pé) associada a dichelobacter nodosus virulento que requer tratamento sistêmico.

União Europeia - português - EMA (European Medicines Agency)

dechra regulatory b.v. - tulatromicina - antibacterianos para uso sistêmico - cattle; pigs; sheep - cattle: treatment and metaphylaxis of bovine respiratory disease (brd) associated with mannheimia haemolytica, pasteurella multocida, histophilus somni and mycoplasma bovis susceptible to tulathromycin. a presença da doença no rebanho deve ser estabelecida antes do tratamento metafatológico. treatment of infectious bovine keratoconjunctivitis (ibk) associated with moraxella bovis susceptible to tulathromycin. pigs: treatment and metaphylaxis of swine respiratory disease (srd) associated with actinobacillus pleuropneumoniae, pasteurella multocida, mycoplasma hyopneumoniae, haemophilus parasuis and bordetella bronchiseptica susceptible to tulathromycin. a presença da doença no rebanho deve ser estabelecida antes do tratamento metafatológico. the product should only be used if pigs are expected to develop the disease within 2–3 days. ovinos: tratamento dos estágios iniciais da pododermatite infecciosa (podridão do pé) associada a dichelobacter nodosus virulento que requer tratamento sistêmico.

União Europeia - português - EMA (European Medicines Agency)

ceva santé animale - inactivated fimbrial adhesins of escherichia coli f4ab, inactivated fimbrial adhesins of escherichia coli f4ac, inactivated fimbrial adhesins of escherichia coli f5, inactivated fimbrial adhesins of escherichia coli f6 - imunológicos para suidae - porcos - for the passive immunisation of progeny by active immunisation of pregnant sows and gilts to reduce clinical signs (severe diarrhoea) and mortality caused by escherichia coli strains expressing the fimbrial adhesins f4ab, f4ac, f5 and f6.

União Europeia - português - EMA (European Medicines Agency)

ceva santé animale - clostridium perfringens type c, beta1 toxoid / clostridium perfringens, type a, alpha toxoid / clostridium perfringens, type a, beta2 toxoid / escherichia coli, fimbrial adhesin f4ab / escherichia coli, fimbrial adhesin f4ac / escherichia coli, fimbrial adhesin f5 / escherichia coli, fimbrial adhesin f6 - immunologicals for suidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) escherichia + clostridium - porcos - for the passive immunisation of progeny by active immunisation of pregnant sows and gilts to reduce:-           clinical signs (severe diarrhoea) and mortality caused by escherichia coli strains expressing the fimbrial adhesins f4ab, f4ac, f5 and f6-           clinical signs (diarrhoea during the first days of life) associated with clostridium perfringens type a expressing alpha and beta 2 toxins-           clinical signs and mortality associated with haemorrhagic and necrotising enteritis caused by clostridium perfringens type c expressing beta1 toxin.

União Europeia - português - EMA (European Medicines Agency)

laboratorios hipra, s.a. - clostridioides difficile toxoid a, clostridioides difficile toxoid b, clostridium perfringens, type a, alpha toxoid - immunologicals for suidae, inactivated bacterial vaccines for pigs, clostridium - porcos - for the passive immunisation of neonatal piglets by means of the active immunisation of breeding sows and gilts:- to prevent mortality and reduce clinical signs and macroscopic lesions caused by clostridioides difficile toxins a and b. - to reduce clinical signs and macroscopic lesions caused by clostridium perfringens type a, alpha toxin.

Portugal - português - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

generis farmacêutica, s.a. - tadalafil - comprimido revestido por película - 20 mg - tadalafil 20 mg - tadalafil - genérico - duração do tratamento: curta ou média duração